These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26723185)

  • 1. Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.
    Siefker-Radtke AO; Campbell MT; Munsell MF; Harris DR; Carolla RL; Pagliaro LC
    Urology; 2016 Mar; 89():83-9. PubMed ID: 26723185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
    Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.
    Bajorin DF
    Eur J Cancer; 2000 Jul; 36 Suppl 2():26-9. PubMed ID: 10908845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
    Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
    Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
    J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Boyle MG; Bajorin DF
    Cancer; 2007 Feb; 109(3):549-55. PubMed ID: 17200962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
    Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
    Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
    Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
    Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
    Hurwitz ME; Markowski P; Yao X; Deshpande H; Patel J; Mortazavi A; Donadio A; Stein MN; Kelly WK; Petrylak DP; Mehnert JM
    Clin Genitourin Cancer; 2018 Dec; 16(6):437-444.e6. PubMed ID: 30177237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.